Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Inge Marie Svane


Inge Marie Svane

Copenhagen University Hospital


Inge Marie Svane, MD, PhD is Professor in Clinical Cancer Immune Therapy at the University of Copenhagen, Director of National Center for Cancer Immune Therapy (CCIT-DK), Herlev and Gentofte Hospital, and Chief Physician specialized in melanoma at the Department of Oncology at Copenhagen University Hospital, Herlev, Denmark. She is also head of the PhD educational program in Clinical Cancer Research at Copenhagen University and head of the Clinical Academic Group in Cancer Immunotherapy, Copenhagen Health Sciences Partners.

Inge Marie Svane has more than 25 years of research experience in cancer immunology and immunotherapy and holds a PhD in basic cancer immunology. She has pioneered the field of cancer immunotherapy in Denmark, building up CCIT-DK, a translational research center in a leading European position. Her focus of expertise is T-cell based adoptive cell therapy and other cellular therapies, cancer vaccines, and immune regulation. CCIT-DK comprise a clean room (GMP) facility headed by Inge Marie Svane enabling manufacturing of in-house clinical grad immunotherapeutic products.

Since 2001 she has initiated more than 20 phase I, II, and III immunotherapeutic trials as academic sponsor. Further, she is national principal investigator on numerous international clinical trials in collaboration with the pharmaceutical industry, primarily within the area of immunotherapy. Inge Marie Svane is co-founder of IO Biotech, a spinout biotech company from Herlev and Gentofte Hospital and the Capital Region of Denmark aiming to develop immune modulating vaccines for cancer therapy. Inge Marie Svane has an extensive cooperative network with scientists and clinicians nationally and internationally and is a frequent speaker at national and international meetings, courses, and conferences.

Inge Marie Svane is key opinion leader on cancer immunotherapy, acknowledging the importance of communication to the public, patient associations, and politicians. She actively supports the European cancer patient coalition as scientific committee member in the Immuno-Oncology Academy. She is member of the scientific committee and faculty on Immunotherapy in the European Society for Medical Oncology, ESMO. Further, she is initiator of a national, scientific network, IMMUNONET, member of the European melanoma group, EORTC, and steering group member of the Danish Melanoma Group heading national treatment guidelines and real-world patient registries.

Inge Marie Svane is co-author of more than 275 scientific publications, including senior author on more than 85 papers in NEJM, Lancet Oncol, Nature Med, Cancer Res, J Immunother Cancer, Br J Cancer, Clin Cancer Res, Oncoimmunology, Eur J Cancer, Cancer Immunol Immunother, Front Immunol, Cancer Immunol Res, and Blood a.o.

ORCiD: 0000-0002-9451-6037

Last update: June 2023

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.